SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a next-generation ADC linker-payload integrating the potent Topoisomerase I inhibitor SN-38 with a cleavable PAB linker for controlled drug release. The PEG8 spacer enhances solubility and pharmacokinetics, while the terminal azide enables bioorthogonal click conjugation to antibodies or biomolecules. An essential, ready-to-conjugate warhead for precision oncology, drug delivery, and ADC development.
Usually ships within 24 hours.